Effects on Su Xiao Jiu Xin Pills in the treatment of patients with acute coronary syndromes undergoing early percutaneous coronary intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003053

Enrollment

Unknown

Registered

2013-01-28

Start date

2013-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndromes

Interventions

Su Xiao Jiu Xin Pills intervention group:Su Xiao Jiu Xin Pills

western medicine group:Western medicine only

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 30-80 years old; 2. Suitable for Percutaneous Coronary Intervention (PCI) therapy, including acute st-elevation myocardial infarction (STEMI) unstable angina (UA) and non st-elevation myocardial infarction (NSTEMI); 3. Conform to the traditional Chinese medicine syndrome differentiation for qi stagnation and blood stasis patients; 4. Be Voluntary subjects and be willing to sign informed consent form; 5. Not experienced taking Su Xiao Jiu Xin Pills.

Exclusion criteria

Exclusion criteria: 1. With severe cardiopulmonary dysfunction, severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia) patients; 2. Combined Severe primary diseases of the heart, liver, brain, kidney and hematopoietic system, or Combined the mentally ill; 3. Pregnancy or prepare pregnancy, breast-feeding women; 4. Known allergy to the experimental drug,or severe allergic constitution; 5. Participated in other clinical trials in the last three months.

Design outcomes

Primary

Measure	Time frame
clinical end point event;urine routine examination;Stool Routine examination;blood coagulation function examination;	—

Secondary

Measure	Time frame
liver function test;renal function test;electrocardiogram;serum lipid level;clinical end point event;myocardial injury biomarker;coronary angiogram;TCM Syndrome efficacy;Seattle Angina Questionnaire;the reduction rate of nitroglycerin;echocardiographic diagnosis;carotid intimamedia thickness;the endothelial function;platelet function;markers of early inflammation;Drug-drug interaction;gene polymorphism;	—

Measure

Time frame

liver function test;renal function test;electrocardiogram;serum lipid level;clinical end point event;myocardial injury biomarker;coronary angiogram;TCM Syndrome efficacy;Seattle Angina Questionnaire;the reduction rate of nitroglycerin;echocardiographic diagnosis;carotid intimamedia thickness;the endothelial function;platelet function;markers of early inflammation;Drug-drug interaction;gene polymorphism;

—

Countries

China

Contacts

Public ContactXiaolong Wang

wxlxy0214@163.com+86 13501991450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026